肿瘤防治的新挑战-肿瘤异质性, 分子分型 及个体化冶疗.ppt
《肿瘤防治的新挑战-肿瘤异质性, 分子分型 及个体化冶疗.ppt》由会员分享,可在线阅读,更多相关《肿瘤防治的新挑战-肿瘤异质性, 分子分型 及个体化冶疗.ppt(58页珍藏版)》请在三一文库上搜索。
1、肿瘤防治的新挑战 (肿瘤异质性, 分子分型, 及个体化冶疗),中国医学科学院 北京协和医学院 肿瘤研究所 肿瘤医院 程书钧,我国恶性肿瘤发病及死亡情况的回顾与预测,预计在2020年,全球新发病例将达1500万(我国占1/5),死亡1000万(我国占1/4),现患病例3000万。,肿瘤防治模式,高危个体 癌前病变 占位病变 预防 予警、发现 手术、放疗、化疗 生物,初级阶段,Wood,LD,et.al(Science,2007,Nov.16,Vol.318:1108) isolated DNA from 11 breast and 11 colorectal tumors and determi
2、ned the sequences based on exons representing 20,857 transcript from 18,191gene. Any gene that was mutated in the tumor but not in normal tissue from the same patients was analyzed in 24 additional tumors. Pathway rather than individual genes appear to govern the course of tumorigenesis. Disruption
3、of a pathway by mutation in any one of its genetic components would presumably lead to similar changes in growth. The 15 driver mutation in an individual tumor likely reflect alterations in a similar number of pathways.,A few gene mountains are mutated in a large proportion of tumors; most genes are
4、 mutated in 5% of tumors represented as hills两个肿瘤突变基因重复的很少, (Science 2007,318: 1108),Greenman,C et al(Nature, 2007,446:153-)reported 1,000 somatic mutations found in the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern o
5、f mutations in individual cancer. Most somatic mutations are likely to be passengers that do not contribute to oncogenesis. However, there was evidence for driver mutation contributing to the development of the cancer studied in approximately 120 genes.,Thomas,RK et al.(Nature genetics,2007,39:347-)
6、determined 238 known oncogen mutation across 1,000 human tumor samples of 17 cancer types. Of 17 oncogens analyzed, they found 14 to be mutated at least once, and 298(30%) samples carried at least one mutation,1). Wood,LD,et.al determined the 乳腺癌和结直肠癌 DNA sequences based on exons of 20,857 transcrip
7、t from 18,191gene. (Science,2007,Nov.16,Vol.318:1108) 2). Thomas RK,et al 分析17类肿瘤 238个oncogenes 的突变(Nature genetics, 2007: 39; 153-) 3). Greenman,C;et al. 分析210个不同人的肿瘤的 518 protein kinase gene exons 的突变 ( Nature, 2007, 446: 153-) 两个肿瘤之间突变基因重复的很少 Pathway rather than individual genes appear to govern
8、the course of tumorigenesis. Disruption of a pathway by mutation in any one of its genetic components would presumably lead to similar changes in growth. The differences are likely to be the basis for the wide variation in tumor behavior and responsiveness to therapy,The epigenetic progenitor model
9、of cancer Stem/progenitor cells表观遗传学(epigenetic)改变; Gatekeeper mutation; Genetic and epigenetic instability Feinberg,AP et al.( Nature Review Genetics,2006,7: 21-33),我们还不清楚一个肿瘤包含有多少个基因的改变,以及相互的作用机理? 但研究已揭示与癌变有关的基因参与的复杂性,造戌了肿瘤病人的个体反应不同,这是肿瘤分子分型和个体化冶疗的基础,肿瘤异质性, 分子型, 及个体化冶疗 Systems biology,基因突变谱 (SNP)
10、(Array CGH) 基因组甲基化谱 基因表达谱 MicroRNAs谱(Oncomirs) 蛋白标志谱 染色体异常 细胞组织,Diffuse large B-cell(DLBCL)(the most common subtype of non-Hodgkins lymphoma) Germinal centre B-like DLBCL, to express genes characteristic of germinal centre B cell, had a significant better survival.(LMO2, BCL6,FN1, expression related
11、 to longer survival) Activated B-like DLBCL, to express genes normally induced during in vitro activation of peripheral blood B cells. (CCND2, SCYA3, BCL2. expression related to shorter survival) ( N. Engl. J. Med. 2004, 300: 1828-1837),Breast cancer patients with the same stage can have markedly di
12、fferent treatment responses. The clinical behaviour (such as lymph node status and histological grade) fail to classify accurately outcome. Chemotherapy or hormonal therapy reduces distant metastases by one-third, however 70-80% of these patients would not developed distant metastases without the ad
13、juvant treatment, these patients may not benefit from the treatment, and may potentially suffer from the side effects. (Nature, 2002,VOl.415, 530),FDA News FOR IMMEDIATE RELEASE P07-13 February 6, 2007 Media Inquiries: . The MammaPrint test uses the latest in molecular technology to predict whether
14、existing cancer will metastasize (spread to other parts of a patients body). 70 genes activity confers information about the likelihood of tumor recurrence.,MicroRNA(miRNAs 300-1000) are an abundant class of negative gene regulators that have been shown to control a wide range of biological function
15、s such as cellular proliferation, differentiation and apoptosis. About half of the annotated human miRNAs map within fragile region of chromosomes, which are areas of the genome that are associated with various human cancers. miRNA mutations or mis-expression correlate with various human cancers and
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 肿瘤防治的新挑战-肿瘤异质性 分子分型 及个体化冶疗 肿瘤 防治 挑战 异质性 分子 个体化
链接地址:https://www.31doc.com/p-2810199.html